Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT). Both saw their shares more than double in 2024, ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Furthermore, should the oral form of VK2735 actually be approved sometime ... As a proxy, Lilly's Mounjaro and Zepbound are on track for $14.7 billion in combined sales for 2024 -- essentially ...

This is particularly interesting because mainstream obesity drugs such as Wegovy and Zepbound are administered ... phase 2 trial for the oral form of VK2735. While this is exciting news on the ...

Lilly began marketing tirzepatide as Mounjaro for diabetes patients in 2022, then as Zepbound for weight management ... tentatively named VK2735, reduced obesity patients' weight by 14.7% after ...

VK2735 is a dual GLP-1/GIP medicine, the same class as Eli Lilly's Zepbound. While that doesn't guarantee success, the company could make even more progress in 2025. Viking Therapeutics should ...

When the company reported VK2735's phase 2 results last year, the stock jumped 121% in one trading session. Viking gave back some of those gains, but still finished the year, as mentioned above, with ...

You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy ... 1 receptor agonists and has a candidate, VK2735, in late-stage clinical trials.